Downregulation of reversion-inducing cysteine-rich protein with Kazal motifs in malignant melanoma: Inverse correlation with membrane-type 1-matrix metalloproteinase and tissue inhibitor of metalloproteinase 2

Melanoma Research

Volumn 24, Issue 1, 2014, Pages 32-39

  Jacomasso, Thiago ^a   Trombetta Lima, Marina ^b   Sogayar, Mari C ^b   Winnischofer, Sheila M B ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

gene expression; matrix metalloproteinases; matrix metalloproteinases inhibitors; melanoma; reversion inducing cysteine rich protein with Kazal motifs; tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UPREGULATION;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; PHENOTYPE; PROGNOSIS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84891951539     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000039     Document Type: Article

References (43)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445:851-857.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174.
3. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69:562-573.
4. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14:2123-2133.
5. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg J-O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011; 278:28-45.
6. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005; 87:307-314.
7. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol 2011; 12:1-7.
8. Stetler-Stevenson WG. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev 2008; 27:57-66.
9. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998; 95:13221-13226.
10. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107:789-800.
11. Sasahara RM, Brochado SM, Takahashi C, Oh J, Maria-Engler SS, Granjeiro JM, et al. Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detect Prev 2002; 26:435-443.
12. Takagi S, Simizu S, Osada H. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 2009; 69:1502-1508.
13. Clark JC, Thomas DM, Choong PF, Dass CR. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007; 26:675-683.
14. van der Jagt MF, Sweep FC, Waas ET, Hendriks T, Ruers TJ, Merry AH, et al. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 2006; 237:289-297.
15. Hsu MC, Chang HC, Hung WC. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 2006; 281:4718-4725.
16. Correa TC, Brohem CA, Winnischofer SM, da Silva Cardeal LB, Sasahara RM, Taboga SR, et al. Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness. J Cell Biochem 2006; 99:156-167.
17. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003; 63:3069-3072.
18. Noda M, Takahashi C. Recklessness as a hallmark of aggressive cancer. Cancer Sci 2007; 98:1659-1665.
19. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, Furcht LT, et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol 2004; 122:167-176.
20. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115:337-344.
21. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11:7234-7242.
22. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008; 6:760-769.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:1-11.
24. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000; 191:245-256.
25. Hsu MY, Elder D, Herlyn M. Melanoma: the Wistar Melanoma (WM) cell lines. In: Masters JR, Palsson B, editors. Human cell culture. the Netherlands: Springer; 2002. pp. 259-274.
26. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485:502-506.
27. Pimiento JM, Larkin EM, Smalley KS, Wiersma GL, Monks NR, Fedorenko IV, et al. Melanoma genotypes and phenotypes get personal. Lab Invest 2013; 93:858-867.
28. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, Shrager J. A melanoma molecular disease model. PLoS One 2011; 6:e18257.
29. Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ. Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol 2012; 132:274-283.
30. Francisco G, Ramos Cirilo PD, Toledo F, Tortelli TC Junior, Chammas R. Melanoma genetics: from susceptibility to progression. In: Duc HT, editor. Melanoma-from early detection to treatment. edn Rijeka/Croatia: Intech; 2013. pp. 83-136.
31. Plocik AM, Graveley BR. New insights from existing sequence data: generating breakthroughs without a pipette. Mol Cell 2013; 49: 605-617.
32. Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 2002; 197:179-187.
33. Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and-2 in patients with malignant melanoma. J Dermatol 2008; 35:206-214.
34. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998; 58:2310-2315.
35. Cruz-Munoz W, Sanchez OH, Di Grappa M, English JL, Hill RP, Khokha R. Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3-/-mice. Oncogene 2006; 25:6489-6496.
36. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, et al. Expression of collagenases-1 and-3 and their inhibitors TIMP-1 and-3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80:733-743.
37. Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989; 4:1363-1374.
38. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
39. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355:51-65.
40. Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, et al. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 1999; 274:21056-21062.
41. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40:1362-1378.
42. Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma. Arch Dermatol Res 2005; 297:154-160.
43. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, et al. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997; 7 (Suppl 2):S35-S42.